UA99729C2 - Heteroaryl amide analogues - Google Patents

Heteroaryl amide analogues

Info

Publication number
UA99729C2
UA99729C2 UAA200913336A UAA200913336A UA99729C2 UA 99729 C2 UA99729 C2 UA 99729C2 UA A200913336 A UAA200913336 A UA A200913336A UA A200913336 A UAA200913336 A UA A200913336A UA 99729 C2 UA99729 C2 UA 99729C2
Authority
UA
Ukraine
Prior art keywords
heteroaryl amide
disorder
amide analogues
analogues
heteroaryl
Prior art date
Application number
UAA200913336A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Раджагопал Бактхаватчалам
Дейвид Си Ил
Скот М. Капитости
Дейвид Дж. Вустроу
Джун Юань
Original Assignee
Х. Луннбек А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Луннбек А/С filed Critical Х. Луннбек А/С
Publication of UA99729C2 publication Critical patent/UA99729C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula la and/or Ib. In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2Xreceptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.
UAA200913336A 2007-08-10 2008-08-11 Heteroaryl amide analogues UA99729C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95525007P 2007-08-10 2007-08-10

Publications (1)

Publication Number Publication Date
UA99729C2 true UA99729C2 (en) 2012-09-25

Family

ID=40351102

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200913336A UA99729C2 (en) 2007-08-10 2008-08-11 Heteroaryl amide analogues

Country Status (14)

Country Link
EP (1) EP2185560A4 (en)
JP (2) JP2010535816A (en)
KR (1) KR20100066422A (en)
CN (1) CN101778850A (en)
AU (1) AU2008286946B2 (en)
BR (1) BRPI0812594A2 (en)
CA (1) CA2691512A1 (en)
CO (1) CO6251319A2 (en)
EA (1) EA020332B1 (en)
IL (1) IL202550A0 (en)
NZ (1) NZ582056A (en)
SG (1) SG183699A1 (en)
UA (1) UA99729C2 (en)
WO (1) WO2009023623A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010237302A1 (en) * 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
WO2012110190A1 (en) * 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
HUE044867T2 (en) 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteostasis regulators
WO2012163456A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) * 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (en) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 Heterocyclic amide derivatives as P2X7 receptor antagonists
US9409917B2 (en) * 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
JOP20130213B1 (en) * 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co Oppositions to the 5-HT3 Future
WO2014091415A1 (en) * 2012-12-12 2014-06-19 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR102232744B1 (en) * 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Indole carboxamide derivatives as p2x7 receptor antagonists
ES2616883T3 (en) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
BR112015019276A2 (en) 2013-02-19 2017-07-18 Pfizer azabenzimidazole compounds as inhibitors of pde4 isoenzymes for the treatment of snc disorders and other disorders
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
TWI644671B (en) * 2013-03-14 2018-12-21 比利時商健生藥品公司 P2X7 regulator
JO3509B1 (en) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv P2x7 modulators
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
CA2918487C (en) * 2013-07-17 2021-08-03 Global Alliance For Tb Drug Development Azaindole compounds, synthesis thereof, and methods of using the same
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
MD20170011A2 (en) 2014-08-06 2017-08-31 Pfizer Inc. Imidazopyridazine compounds
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
CA2962429C (en) 2014-09-29 2023-01-03 Takeda Pharmaceutical Company Limited Crystalline form of 1-(1-methyl-1h-pyrazol-4-yl)-n-((1r,5s,7s)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
EP3233841A1 (en) * 2014-12-15 2017-10-25 Merck Patent GmbH Indole and azaindoles derivatives and their use in neurodegenerative diseases
JP6462493B2 (en) 2015-05-29 2019-01-30 株式会社デンソー Approach determination device, approach determination method
CA3010615C (en) 2016-01-14 2024-02-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
TW201819361A (en) 2016-09-03 2018-06-01 印度商托仁特生技有限公司 Novel indazole compounds
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
KR20210069079A (en) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. monoacylglycerol lipase modulator
JP7697934B2 (en) 2019-09-30 2025-06-24 ヤンセン ファーマシューティカ エヌ．ベー． Radiolabeled MGL PET Ligand
BR112022019077A2 (en) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv MONOACYLGLYCEROL LIPASE MODULATORS
CN116323581B (en) * 2020-09-22 2025-05-30 苏州恩华生物医药科技有限公司 Indole derivatives and use thereof
CN119156388A (en) * 2022-04-15 2024-12-17 海南先声再明医药股份有限公司 Membrane associated tyrosine and threonine kinase inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2557342A1 (en) * 1975-12-19 1977-06-30 Hoechst Ag BASIC SUBSTITUTED INDOLDER DERIVATIVES AND THE PROCESS FOR THEIR PRODUCTION
DE2931323A1 (en) * 1979-08-02 1981-02-26 Kali Chemie Pharma Gmbh NEW N-AMINOALKYLINDOL DERIVATIVES AND THEIR SALTS
DE3131527A1 (en) * 1981-08-08 1983-02-24 Kali-Chemie Pharma Gmbh, 3000 Hannover 1-PHENYL-2-AMINOCARBONYLINDOL COMPOUNDS AND METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
TW229140B (en) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
DK1042287T3 (en) * 1997-12-24 2005-08-15 Aventis Pharma Gmbh Indole derivatives as inhibitors of factor Xa
CZ20013608A3 (en) * 1999-04-09 2002-05-15 Astrazeneca Ab Adamantane derivatives
MXPA02003436A (en) * 1999-10-07 2002-08-20 Amgen Inc Triazine kinase inhibitors.
WO2001058869A2 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
EP1310488A4 (en) * 2000-08-09 2005-08-10 Mitsubishi Pharma Corp CONDENSED BICYCLIC AMIDE COMPOUNDS AND MEDICAL USES THEREOF
CN101284773A (en) * 2001-08-09 2008-10-15 小野药品工业株式会社 Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
PL375149A1 (en) * 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
DE10253426B4 (en) * 2002-11-15 2005-09-22 Elbion Ag Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and methods for their preparation
AU2003303217A1 (en) * 2002-12-20 2004-07-14 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
FR2857966A1 (en) * 2003-07-24 2005-01-28 Aventis Pharma Sa New piperazine and tetrahydropyridine derivatives are tubulin polymerization inhibitors used for treating cancer and disaggregating cell masses derived from vascular tissue
SE0302192D0 (en) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (en) * 2004-08-05 2006-09-15 Sanofi Synthelabo N- (1H-INDOLYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
FR2880625B1 (en) * 2005-01-07 2007-03-09 Sanofi Aventis Sa N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
TW200700387A (en) * 2005-03-21 2007-01-01 Akzo Nobel Nv 1-benzylindole-2-carboxamide derivatives
FR2888847B1 (en) * 2005-07-22 2007-08-31 Sanofi Aventis Sa N- (HETERIARYL) -1-HETEORARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION
WO2007079239A2 (en) * 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
WO2007098214A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors

Also Published As

Publication number Publication date
EA020332B1 (en) 2014-10-30
CA2691512A1 (en) 2009-02-19
JP2015110566A (en) 2015-06-18
AU2008286946A1 (en) 2009-02-19
EA200971085A1 (en) 2010-06-30
EP2185560A1 (en) 2010-05-19
WO2009023623A1 (en) 2009-02-19
IL202550A0 (en) 2010-06-30
NZ582056A (en) 2012-08-31
CN101778850A (en) 2010-07-14
AU2008286946B2 (en) 2013-11-21
KR20100066422A (en) 2010-06-17
CO6251319A2 (en) 2011-02-21
BRPI0812594A2 (en) 2015-06-23
EP2185560A4 (en) 2011-10-05
JP2010535816A (en) 2010-11-25
SG183699A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
UA99729C2 (en) Heteroaryl amide analogues
WO2009108551A3 (en) Heteroaryl amide analogues
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MY172926A (en) Tetrahydropyrazolopyrimidine compounds
MX2009005462A (en) 7,8-saturated-4,5-epoxy-morphinanium analogs.
MX2010008714A (en) Amide derivatives as positive allosteric modulators and methods of use thereof.
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
MY148657A (en) Trpv1 antagonists and uses thereof
WO2014120808A8 (en) Pyridone amides as modulators of sodium channels
MX342423B (en) 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients.
MY162146A (en) Pharmaceutical composition
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
SI2024368T1 (en) 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain
TN2012000059A1 (en) Compositions comprising tramadol and celecoxib in the treatment of pain
WO2009120919A3 (en) Fenofibrate dosage forms
UA116894C2 (en) Novel pyrazine derivatives as cb2 receptor agonists
GB2477256A (en) Medicament and method of diagnosis
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
MY152685A (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
EP4218786A3 (en) Opiorphin for use as analgesic agent
MX2010001075A (en) N-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors.
HK1201839A1 (en) Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands
SI2146951T1 (en) Novel rar receptor agonist ligands and use thereof in human medicine and cosmetics
MX385460B (en) Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol